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See related comment by Neil Hall, http://genomebiology.com/2014/15/2/104The battle for humanity
Human (clinical) genome sequencing is the biggest poten-
tial market in DNA sequencing, and it is this market that
all of the sequencing companies are striving to capture. In
another article in this issue of Genome Biology, Neil Hall
expresses some concern over the limitation of Illumina’s
newly announced Hiseq X Ten platform to human (http://
genomebiology.com/2014/15/2/104); indeed, at face value
this does appear strange. The fact that Illumina have pre-
sented PhiX data from the X Ten confirms that there is
no limitation inherent to the technology. The limitation is
one of licensing. However, those involved in human
genome sequencing will not be surprised by the move.
Human genome sequencing has been far cheaper than
other genome sequencing for many years, and the X Ten is
simply an extension of that pattern. The reason for this is
Complete Genomics, a sequencing company whose tech-
nology is currently limited to human genomics. It’s cheaper
to sequence a human genome with Complete Genomics
than it is to sequence the same genome on your own Illu-
mina instruments. Up until now, Illumina’s answer to this
has been to sequence human genomes in house, matching
Complete Genomics’ price. By my estimate, sequencing
human genomes at Illumina’s in-house sequencing services
is approximately 50% of the cost of sequencing the same
genomes on your own Illumina instruments. Illumina are
actually undercutting their own customers on human gen-
ome sequencing, and have been for years. I doubt this is a
position they enjoy, but this is how they have chosen to
compete with Complete Genomics.
So human genome sequencing has always been different,
and the X Ten’s limitation is simply an extension of that.
It’s just business
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months following its publication. After this tim
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creativecommons.org/publicdomain/zero/1.0/all at £100 per pair. You dominate the market. Then a
competitor comes to your attention - they also make
shoes, but at present, they only make sports shoes. They
sell their sports shoes at £50 per pair. What do you do?
Your competitor only sells sports shoes - you have to com-
pete, so reducing the cost of your sports shoes to £50 per
pair is a no-brainer, but there is no competitor in the
market for the other types of shoe. You can still sell those
at £100 per pair. Would you also reduce the cost of all your
other shoes? I don’t think you would; or if you did, then
you wouldn’t be a very good businessman.
Illumina have a viable competitor in human genome
sequencing, and so with the X Ten, they are competing
with Complete Genomics for the human genome sequen-
cing market. However, to expect them to reduce costs in
other markets, and therefore reduce their profits, when
they do not face any realistic competitor in those markets,
is to expect Illumina to have poor business acumen. It is
to expect Illumina to make a decision that would damage
their business and reduce their profits. Illumina are a busi-
ness, first and foremost. When working with Illumina I
have always found them to be helpful and collaborative,
but I am under no illusions: they act in this way because it
benefits their business. As scientists, we cannot and
should not expect companies to behave in any other way.
They have an obligation to their shareholders to make a
profit. None of us should be surprised by the X Ten’s
human limitation. In fact, it is an entirely logical step.
For me, an interesting question is how the other
markets react. For example, will those working in pig ge-
nomics (the pig genome is approximately the same size
as the human genome) continue to pay $7,000 for a 30x
genome when they know that their human counterparts
can get the same for $1,000? Or will they say, ‘No, we
will wait until the $1,000 pig genome is available’. If the
other sequencing communities decide to hold onto their
money, waiting for the X Ten license to be relaxed, then
this will harm the current Hiseq 2500 market and may
influence Illumina’s future strategy. Alternatively, should
Complete Genomics become available to other species,
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What has not been discussed up until now is the fact that
Illumina have never released a system that is already at its
peak performance; to put it simply, the Hiseq X will get
better - run times will get faster, read lengths will get lon-
ger and read numbers will rise. The Hiseq X Ten can de-
liver the $1,000 genome now, but even cheaper human
genomes are built in.
Of course, the Hiseq X license will relax at some point.
At the moment, only human sequencing is available and
only whole genome (using the TruSeq nano protocol).
Eventually, however, the X system will be opened up - both
to other types of sequencing (RNA-seq, exomes and so on)
and to other species. Not only will we have the $1,000 gen-
ome, but the $100 exome, the $50 RNA-Seq. What Illu-
mina will want to hear is that, as sequencing gets cheaper,
researchers will either sequence deeper (more reads per
sample) or broader (more samples at existing read depths).
Users will eventually be able to purchase individual Hiseq
X systems, rather than the current minimum buy of a clus-
ter of ten, and the new machine is effectively the replace-
ment for the Hiseq 2500. In 18 to 24 months, I anticipate
Hiseq 2500 owners to trade them in for Xs - either that or
find themselves undercut by other facilities.
It will be really interesting to see how Life Technolo-
gies responds, as manufacturers of the Ion Torrent se-
quencing platforms (the Personal Genome Machine and
the Proton). Their key advantage is speed, with the Ion
platforms carrying out the sequencing component in
hours rather than days. However, the throughput and
cost-per-base do not match current Illumina platforms,
never mind the new ones. To remain a viable business,
Life Technologies must respond. Both companies may
also face competition from Roche, a global healthcare
company who recently announced an intriguing agree-
ment with Pacific Biosciences (http://investor.pacific-
biosciences.com/releasedetail.cfm?ReleaseID=793199) to
develop DNA sequencing products for clinical diagnos-
tics. As a large multinational corporation, Roche have
the financial clout to be a disruptive influence in the
market. Having previously made moves to purchase Illu-
mina, the renewed interest shown by Roche is an early
signal of intent to move into human clinical sequencing.
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